New regulatory guidance released by the MHRA in collaboration with NICE in late 2025 has redefined the UK Digital Mental Health Market landscape for 2026. The guidance clarifies that any digital mental health technology (DMHT) that diagnoses or treats conditions using complex software must now be regulated as Software as a Medical Device (SaMD).

This change divides the market into two distinct tiers:

1. Class I (Low Risk): Wellness and mood-tracking apps that can be self-certified.

2. Class IIa, IIb, and III (Higher Risk): AI-driven diagnostic tools and therapeutic software that require independent assessment by an Approved Body. This framework has increased consumer trust but also raised the "barrier to entry," favoring established firms like thymia and Ieso Digital Health that have the clinical data to meet these rigorous safety standards.

FAQ:

• Question: What is SaMD?

• Answer: Software as a Medical Device—software intended for medical purposes that must meet strict safety and efficacy laws.

• Question: Who regulates these apps in the UK?

• Answer: The MHRA (Medicines and Healthcare products Regulatory Agency).